CGBS GbR
- Address
- Im Pruefling 21-25, Bornheim, 60389 Frankfurt, Germany
Digestive System Diseases
The gastroenterology department at CGBS GbR concentrates on digestive system diseases such as irritable bowel syndrome, evaluating oral probiotic therapies that aim to lessen symptom frequency and improve quality of life.
- Probiotic‑based interventions for IBS
- Placebo‑controlled efficacy studies
- Safety assessments of novel oral agents
By partnering with local clinicians in Frankfurt, the site offers patients access to cutting‑edge research that tests new treatments and monitors tolerability.
Immune System Diseases
In addition to digestive disorders, the center investigates immune system diseases affecting the gut, notably microscopic colitis, seeking steroid‑free options that sustain clinical remission.
- Steroid‑sparing therapeutic agents
- Remission maintenance trials
- Patient‑reported outcome measures
Double‑blind, placebo‑controlled designs ensure rigorous evaluation of safety and effectiveness, expanding therapeutic choices for chronic colitis patients.
Nutritional and Metabolic Diseases
Although the primary focus remains gastrointestinal, nutritional and metabolic diseases are examined to understand how diet and microbiome modulation influence gut health.
- Microbiome‑targeted nutrition strategies
- Metabolic profiling in IBS cohorts
- Impact of dietary supplements on symptom control
This interdisciplinary perspective links metabolic status with digestive symptom management, offering a holistic approach for patients at the Frankfurt clinic.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CGBS GbR
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide. | Sanofi-Aventis Recherche & Developpement | Phase II | Recruiting | Oct 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| SAR444336 | 1 | Unknown | 2025-10-28 | 2025-10-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.